Skip to main content
Toggle navigation
Login
Search
Home
Tweets by 2023 IKCS: Europe
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Therapeutics- Local (Primary and Metastases)
Home
Therapeutics- Local (Primary and Metastases)
Therapeutics- Local (Primary and Metastases)
Type here to filter the list
32: Clinical benefit of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after checkpoint inhibitor (CPI) therapy: interim results from the Phase 2 CaboPoint trial
Favorite